Carsgen Therapeutics Limited
$1.72
2
-$0.48-21.82% Monday 20:00
Statistics
Day High
2.2
Day Low
2.2
52W High
2.2
52W Low
0.76
Volume
200
Avg. Volume
0
Mkt Cap
990.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Apr 20
$0.25
Oct 19
$0.14
Apr 19
$0.29
Oct 18
$0.15
Apr 18
$0.3
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
6MarExpected
Expected EPS
-0.0200144
Actual EPS
-0.0057184
Financials
-2,025.62%Profit Margin
Unprofitable10.81MRevenue
-218.96MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CRTHF. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
About
CARsgen Therapeutics Holdings Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies and solid tumors in China and the United States. The company is involved in developing CT053, an autologous CAR-T product candidate that is in pivotal Phase II trial for the treatment of relapsed/refractory multiple myeloma in China; CT041, an autologous CAR-T product candidate that is in Phase Ib/II clinical trial for advanced gastric/gastroesophageal junction cancer and pancreatic cancer in China, as well as in Phase Ib clinical trial for advanced gastric or pancreatic cancer in the United States; and CT011, an autologous CAR-T product candidate that is in Phase I clinical trial for patients with Glypican-3 positive advanced hepatocellular carcinoma. It is also developing CT032, an autologous CAR-T products candidate that is in Phase I/II clinical trial for the treatment of B cell Non-Hodgkin's lymphoma in China; AB011, a humanized monoclonal antibody product candidate that is in Phase I clinical trial for the treatment of CLDN18.2 positive solid tumors in China; and CT017, an autologous Glypican-3-targeted CAR-T product candidate for the treatment of hepatocellular carcinoma, as well as other product candidates for the treatment of solid tumors. The company was founded in 2014 and is headquartered in Shanghai, China.
Show more...
CEO
Dr. Zonghai Li M.D., Ph.D.
Country
KY
ISIN
KYG1996C1006
Listings
0 Comments
Share your thoughts
FAQ
What is Carsgen Therapeutics Limited stock price today?▼
The current price of CRTHF is $1.72 USD — it has decreased by -21.82% in the past 24 hours. Watch Carsgen Therapeutics Limited stock price performance more closely on the chart.
What is Carsgen Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Carsgen Therapeutics Limited stocks are traded under the ticker CRTHF.
What is Carsgen Therapeutics Limited market cap?▼
Today Carsgen Therapeutics Limited has the market capitalization of 990.55M
When is the next Carsgen Therapeutics Limited earnings date?▼
Carsgen Therapeutics Limited is going to release the next earnings report on August 25, 2026.
What were Carsgen Therapeutics Limited earnings last quarter?▼
CRTHF earnings for the last quarter are -0.01 USD per share, whereas the estimation was -0.02 USD resulting in a +71.43% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Carsgen Therapeutics Limited revenue for the last year?▼
Carsgen Therapeutics Limited revenue for the last year amounts to 10.81M USD.
What is Carsgen Therapeutics Limited net income for the last year?▼
CRTHF net income for the last year is -218.96M USD.
Does Carsgen Therapeutics Limited pay dividends?▼
Yes, CRTHF dividends are paid semi-annual. The last dividend per share was 0.22 USD. As of today, Dividend Yield (FWD)% is 0%.
When did Carsgen Therapeutics Limited complete a stock split?▼
Carsgen Therapeutics Limited has not had any recent stock splits.
Where is Carsgen Therapeutics Limited headquartered?▼
Carsgen Therapeutics Limited is headquartered in Shanghai, KY.